$Johnson & Johnson (JNJ.US)$will report Q4 numbers next Wednesday (Jan. 22) at a time when the medical company’s stock has been under the weather, falling back some 14% since early September even as the S&P 500 gained about 7%. What does JNJ's technical and fundamental analysis say could happen from here? Let's look: Johnson & Johnson's Fundamental Analysis The Street is looking for JNJ to report $2.04 in adjusted Q4 earnings per sha...
Overall, the market pulled a fast one on traders on Monday. The S&P 500 started down but built into a climb by the end of the day. Just past 4 pm ET the$S&P 500 Index (.SPX.US)$climbed 0.16%, the$Dow Jones Industrial Average (.DJI.US)$was climbing 0.86%, and the$Nasdaq Composite Index (.IXIC.US)$fell 0.38%. MACRO In macroeconomic news this week, watch for Fed speakers, CPI inflation data on Wednesday, and Retail sale data on Thursday. SECTORS This week is the s...
105106443
74917530
:
Nvidia Slams Biden ‘Overreach’ And Praises Trump—As AI Stock Enters Correction Territory And Nvidia official statements NVIDIA Statement on the Biden Administration’s Misguided 'AI Diffusion' Rule
74917530
105106443
:
Can this affect quantum science and technology? wondering what the scope of the restriction is, they mention advanced chips used to develop AI.
Happy Monday, January 13th. The market began the week falling, but you'll never guess why: here's the Live Stock news. $Moderna (MRNA.US)$is falling 21% on Monday, the lowest percentage decliner on the S&P 500 after the firm updated its 2025 guidance, slashing its sales and revenue guidance by $1B, from a range of $2.5-$3.5B it gave in Sept. $Micron Technology (MU.US)$was one of the largest percentage ...
LittleSoldier
:
What on earth makes you think this is a Happy Monday, unless your a Shorter, there is nothing happy going on ! Red Red Red Sea of Red! Green is Happy Red is Mad!!
Morning Movers Gapping up $Lululemon Athletica (LULU.US)$shares climbed 3.9% after the company raised its current-quarter targets, driven by strong holiday-season demand for its apparel. $Enfusion (ENFN.US)$shares surged 12% after Clearwater Analytics (NYSE:CWAN), which rose 1.7%, announced a $1.5 billion cash-and-stock acquisition of the investment management platform. $Intra-Cellular Therapies (ITCI.US)$shares skyrocketed 35% ...
35
6
10
Report
Mohmad kabir Hossen
:
First of all, we need to make a registration, understand the current profit and loss situation of your stock, and then make a targeted strategic evaluation, after the evaluation is completed, and then give you a unified strategy plan
Intra-Cellular Therapies is nearing breakeven, contingent on maintaining a 57% annual growth rate. Its lack of debt, unusual for a pharma company, reduces investment risk.
Benson_188 : moomoo 2025 Spring Festival red envelope! Test your luck and win up to 888* >> https://j.moomoo.com/023qve
CNNT : Enjoy reading about these stocks that are not on hype-seeking investors' radar. TQ.